{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(1)"],"submitter":["Sanchez MF"],"funding":["Ferring Pharmaceuticals, Denmark"],"pubmed_abstract":["<h4>Purpose</h4>To explore the efficacy and safety of individualized follitropin delta dosing, based on serum anti-Müllerian hormone (AMH) concentration and bodyweight, in a long gonadotropin-releasing hormone (GnRH) agonist protocol.<h4>Methods</h4>Clinical outcomes after one treatment cycle are reported in women with AMH: 5-35 pmol/L. Oocytes were inseminated by intracytoplasmic sperm injection, blastocyst transfer was on Day 5 and remaining blastocysts were cryopreserved. Data collection included live births and neonatal health follow-up for all fresh/frozen transfers performed within one year after treatment allocation.<h4>Results</h4>In total, 104 women started stimulation, of whom 101 had oocyte recovery and 92 had blastocyst transfer. The average daily dose of follitropin delta was 11.0 ± 1.6 µg and the duration of stimulation was 10.3 ± 1.6 days. The mean number of oocytes was 12.5 ± 6.4, the mean number of blastocysts was 5.1 ± 3.4, and 85% had at least one good-quality blastocyst. Following mostly single blastocyst transfer (95%), the ongoing pregnancy rate was 43%, the live-birth rate was 43%, and the cumulative live-birth rate was 58% per started stimulation. There were 6 cases of early OHSS (5.8%) graded as mild (n = 3) and moderate (n = 3) and 6 cases of late OHSS (5.8%) graded as moderate (n = 3) and severe (n = 3).<h4>Conclusion</h4>In this first evaluation of the individualized follitropin delta dosing in a long GnRH agonist protocol, the cumulative live-birth rate was high. A randomized trial comparing follitropin delta in a long GnRH agonist protocol versus in a GnRH antagonist protocol should provide further insight into the efficacy and safety of this treatment option.<h4>Trial registration number</h4>NCT03564509; June 21, 2018."],"journal":["Reproductive biology and endocrinology : RB&E"],"pagination":["45"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10185461"],"repository":["biostudies-literature"],"pubmed_title":["Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol."],"pmcid":["PMC10185461"],"pubmed_authors":["Mannaerts B","Larsson P","Sanchez MF","Bosch E","Serrano MF","Velasco JAG","Lopez ES"],"additional_accession":[]},"is_claimable":false,"name":"Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol.","description":"<h4>Purpose</h4>To explore the efficacy and safety of individualized follitropin delta dosing, based on serum anti-Müllerian hormone (AMH) concentration and bodyweight, in a long gonadotropin-releasing hormone (GnRH) agonist protocol.<h4>Methods</h4>Clinical outcomes after one treatment cycle are reported in women with AMH: 5-35 pmol/L. Oocytes were inseminated by intracytoplasmic sperm injection, blastocyst transfer was on Day 5 and remaining blastocysts were cryopreserved. Data collection included live births and neonatal health follow-up for all fresh/frozen transfers performed within one year after treatment allocation.<h4>Results</h4>In total, 104 women started stimulation, of whom 101 had oocyte recovery and 92 had blastocyst transfer. The average daily dose of follitropin delta was 11.0 ± 1.6 µg and the duration of stimulation was 10.3 ± 1.6 days. The mean number of oocytes was 12.5 ± 6.4, the mean number of blastocysts was 5.1 ± 3.4, and 85% had at least one good-quality blastocyst. Following mostly single blastocyst transfer (95%), the ongoing pregnancy rate was 43%, the live-birth rate was 43%, and the cumulative live-birth rate was 58% per started stimulation. There were 6 cases of early OHSS (5.8%) graded as mild (n = 3) and moderate (n = 3) and 6 cases of late OHSS (5.8%) graded as moderate (n = 3) and severe (n = 3).<h4>Conclusion</h4>In this first evaluation of the individualized follitropin delta dosing in a long GnRH agonist protocol, the cumulative live-birth rate was high. A randomized trial comparing follitropin delta in a long GnRH agonist protocol versus in a GnRH antagonist protocol should provide further insight into the efficacy and safety of this treatment option.<h4>Trial registration number</h4>NCT03564509; June 21, 2018.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2025-04-04T10:19:43.976Z","creation":"2025-02-19T00:12:37.729Z"},"accession":"S-EPMC10185461","cross_references":{"pubmed":["37194068"],"doi":["10.1186/s12958-023-01090-w"]}}